Brief: Sensorion Announces Oral Presentation At European Histamine Research Society

Sensorion SA

17/05/2019 06:51

May 17 (Reuters) - SENSORION SA  ALSEN.PA :
    * SENSORION ANNOUNCES ORAL PRESENTATION AT THE EUROPEAN
HISTAMINE
RESEARCH SOCIETY
    * WILL COVER TRANSLATIONAL DEVELOPMENT OF SELIFORANT
STARTING FROM
RESULTS OF IN VITRO AND IN VIVO PRECLINICAL MODELS UP UNTIL
CURRENT PROOF-OF-CONCEPT, CLINICAL TRIAL STAGE ONGOING IN AUV
PATIENTS (PHASE 2)
    * SELIFORANT (SENS-111) IS A NOVEL FIRST-IN-CLASS H4
RECEPTOR
ANTAGONIST
    * CONSISTENCY BETWEEN PHARMACOKINETIC/PHARMACODYNAMIC
(PK/PD)
RELATIONSHIPS PREDICTED FROM PRECLINICAL MODELS OF SEVERE
VERTIGO AND LOCAL TARGET EXPOSURE ASSESSMENT IN A PHASE 1B
CLINICAL TRIAL
    * CONFIRMED LACK OF SEDATION IN BOTH PRECLINICAL AND
CLINICAL
PHASE 2 SETTING

Source text for Eikon:  ID:nBwbppfya 
Further company coverage:  ALSEN.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))